Acumen Pharmaceuticals (ABOS) director awarded RSUs and options for RA Capital
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Stoppel Laura reported acquisition or exercise transactions in this Form 4 filing.
Acumen Pharmaceuticals director Laura Stoppel reported equity awards tied to RA Capital-managed vehicles. She was granted 35,500 restricted stock units (RSUs), each representing one share of common stock, and 53,250 stock options with a strike price of $2.29 per share.
The RSUs and options vest in full on the earlier of the first anniversary of the June 3, 2026 grant date or the 2027 annual stockholder meeting, subject to her continuous service. Under her arrangement with RA Capital Management, L.P., any shares or cash from these awards benefit RA Capital Healthcare Fund, RA Capital Nexus Fund II and a separately managed account, and she disclaims beneficial ownership of the underlying stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Stoppel Laura
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 53,250 | $0.00 | -- |
| Grant/Award | Common Stock | 35,500 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 53,250 shares (Direct, null);
Common Stock — 48,300 shares (Direct, null)
Footnotes (1)
- Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option and RSUs for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
RSU award: 35,500 RSUs
Stock options granted: 53,250 options
Option exercise price: $2.29 per share
+3 more
6 metrics
RSU award
35,500 RSUs
Each RSU equals one share of common stock
Stock options granted
53,250 options
Right to buy Acumen common stock
Option exercise price
$2.29 per share
Conversion or exercise price for options
Option expiration
June 3, 2036
Expiration date of granted options
Common stock after grant
48,300 shares
Total common shares following RSU award
Underlying option shares
53,250 shares
Common shares underlying the options
Key Terms
restricted stock unit ("RSU"), continuous service, conversion or exercise price, beneficial ownership, +1 more
5 terms
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share"
continuous service financial
"will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service"
conversion or exercise price financial
"conversion_or_exercise_price": "2.2900""
beneficial ownership financial
"The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
separately managed account financial
"and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock"
A separately managed account (SMA) is a personalized investment portfolio owned by a single investor and run by a professional manager who buys and sells securities on that investor’s behalf. It matters to investors because an SMA offers tailored asset selection, tax handling, and transparency—like hiring a personal chef who prepares meals to your dietary needs rather than sharing a set menu—so you can align holdings with your goals and see exactly what you own.
FAQ
What did Acumen Pharmaceuticals (ABOS) report in this Form 4?
The filing reports equity awards associated with director Laura Stoppel. She received 35,500 RSUs and 53,250 stock options, both linked to Acumen Pharmaceuticals common stock, for the benefit of RA Capital-managed investment vehicles rather than as a traditional open-market purchase.
How many RSUs were granted in the Acumen (ABOS) Form 4 filing?
The Form 4 shows a grant of 35,500 restricted stock units. Each RSU represents a contingent right to receive one share of Acumen Pharmaceuticals common stock, vesting on the earlier of the first anniversary of grant or the company’s 2027 annual stockholder meeting.
What are the key terms of the stock options reported for Acumen (ABOS)?
The filing discloses 53,250 stock options with a conversion price of $2.29 per share. These options vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting and expire on June 3, 2036, subject to continuous service.
Who ultimately benefits from the RSUs and options in this Acumen (ABOS) filing?
According to the footnotes, the RSUs and options are held for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund II and a separately managed account. Any net stock or cash received offsets advisory fees, and Laura Stoppel disclaims beneficial ownership of the underlying shares.
Does the Acumen (ABOS) Form 4 indicate open-market buying or selling?
No open-market buying or selling is reported. The transactions are coded as awards, reflecting grants of RSUs and stock options rather than purchases or sales, and they are structured for the benefit of RA Capital-managed investment vehicles under an existing arrangement.
What is Laura Stoppel’s reported common stock position after these awards?
The Form 4 lists 48,300 shares of Acumen Pharmaceuticals common stock following the RSU grant. However, the footnotes state she must turn over any net stock or cash to RA Capital’s vehicles and therefore disclaims beneficial ownership of these securities.